Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- 30 April 2009
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 113 (1), 21-27
- https://doi.org/10.1016/j.ygyno.2008.12.003
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactinGynecologic Oncology, 2007
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancerCancer, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Bead-Based ELISA for Validation of Ovarian Cancer Early Detection MarkersClinical Cancer Research, 2006
- Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal CancerDrugs, 2006
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences of the United States of America, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000